Toy Andrew sold $1.7M of CLOV

Toy Andrew (Chief Executive Officer) sold 313,476 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.32 ($1.67M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Toy Andrew
Published Jul 1, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity (size, price, and post-sale holdings) but does not include new fundamentals (earnings, guidance, litigation, or operational updates).

02

Market read

This is a fresh, primary-source insider-sale print that may slightly influence sentiment, but it is unlikely to drive a major repricing absent additional catalysts.

03

What to watch

Traders may overreact to insider sales; the key nuance is the 10b5-1 pre-arrangement, which often makes the timing less informative.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 (filed 2026-07-01) insider sale disclosure

Background

The article is a SEC Form 4 insider transaction for Clover Health Investments, Corp./DE (CLOV), reported as an open-market sale by the CEO.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Toy Andrew filed a Form 4 open-market sale of 313,476 shares at $5.3200 on 2026-07-01.

Expected impact

Likely limited, short-lived impact unless follow-on selling or plan details change.

Evidence & confidence

The filing is primary-source and time-stamped, but it explicitly states a pre-arranged Rule 10b5-1 plan, which reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • CLOVER HEALTH INVESTMENTS, CORP. /DE

    Subject of the Form 4 insider transaction; CEO sale disclosed on 2026-07-01.

  • Toy Andrew

    Chief Executive Officer and director who sold 313,476 shares at $5.3200 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.